PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 3, 2014Frontiers in Pharmacology8 citationsOpen Access

CaMKII comes of age in cardiac health and disease

Design

Review

Key result

CaMKII has emerged as a key signaling molecule in the heart, and its inhibition represents a promising therapeutic target for preventing heart failure progression and arrhythmias.

Authors

EGEleonora GrandiAEAndrew G. EdwardsAHAnthony W. Herren

Discussion

Loading...

Member takes

Overview

CaMKII inhibition merits targeted development; leaves open whether it improves outcomes in heart failure or arrhythmias.

PICO

P
Population
Heart failure, arrhythmia, myocardial hypertrophy
I
Intervention / Comparator
CaMKII inhibition

Limitations

  • Current pharmacological tools for CaMKII inhibition are limited.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Grandi et al. (2014) conducted an editorial in Heart failure, arrhythmia, myocardial hypertrophy. CaMKII inhibition was evaluated. CaMKII has emerged as a key signaling molecule in the heart, and its inhibition represents a promising therapeutic target for preventing heart failure progression and arrhythmias.

synapsesocial.com/papers/6a93cb02bbbb721b13fc144bhttps://doi.org/10.3389/fphar.2014.00154
Ask AI
Helpful
Bookmark
Share
View Full Paper